Stock Analiz

Medifast Inc. MED

Packaged Foods · data as of November 13, 2026

$12.97Market cap $145M
Open the interactive analysis →

Medifast Inc. (MED) is a consumer staples company listed in the US with a market value of about $145M. In the twelve months to September 30, 2026 it had revenue of $300M and net income of -$41M, a net margin of -13.6%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -16% a year, a 5-year average ROIC of 38%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 70% below the current price.

About Medifast

Medifast is listed in the US and classified in packaged foods. Revenue went from $285M in 2014 to $386M in 2025, growth of about 2.8% a year. It was profitable in 9 of the last 10 years in our data. Its share count fell by 3% over three years (buybacks). It spends 1% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth0/5
Track record1/5
Financial health2/5
Shareholder returns4/5

Checks passed

  • 5-year average ROIC above 12%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets
  • Pays a dividend
  • Share count down over 3 years (buybacks)
  • Dividend 3 years in a row
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.5
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.12%
FCF yield-2.7%
Shareholder yield0.1%
Intrinsic value vs. price−70%

Growth and quality

Revenue growth (1 yr)-36.0%
Revenue growth (5 yrs, per year)-16.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)-80.8%
Net margin (5-yr avg.)4.9%
ROIC (5-yr avg.)37.7%
Profitable years (of last 10)9
Years paying a dividend10

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$300M$386M$602M$1.1B$1.6B$1.5B$935M$714M$501M$302M$275M
Net income-$41M-$19M$2M$99M$144M$164M$103M$78M$56M$28M$18M
Free cash flow-$4M$1M$17M$141M$178M$60M$139M$74M$56M$40M$22M
EPS (diluted)$-3.69$-1.70$0.19$9.10$12.73$13.89$8.68$6.43$4.62$2.29$1.49
Net margin-13.6%-4.8%0.4%9.3%9.0%10.8%11.0%10.9%11.1%9.2%6.5%
ROIC—-5.4%0.7%43.7%79.6%69.8%61.0%64.8%44.9%25.6%18.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Medifast stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 70% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Medifast pay a dividend?

Yes. The dividend yield is about 0.12%, and it has paid dividends for 10 years in our data.

Is Medifast a good stock to buy?

We do not give buy or sell advice. Medifast scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.